New hope for lung transplant patients battling deadly rejection
NCT ID NCT06990711
Summary
This early-stage trial is testing whether adding a new medication called siltuximab to standard treatment is safe for lung transplant patients experiencing antibody-mediated rejection. The study will enroll 30 hospitalized adults who have recently been diagnosed with this type of rejection. The main goal is to check for serious side effects and determine the best dose, as this type of rejection currently has very poor survival rates despite existing treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY MEDIATED REJECTION OF LUNG TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Utah
RECRUITINGSaint Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School, of Medicine, Barnes-Jewish Hospital
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.